BEIJING, Aug. 29, 2013 /PRNewswire-FirstCall/
-- China Biologic Products, Inc. (Nasdaq: CBPO, "China
Biologic" or the "Company"), a leading fully integrated
plasma-based biopharmaceutical company in China, is scheduled to participate in the
upcoming conferences:
- Credit Suisse Asian Healthcare Conference, to be held
September 3, 2013 at the Credit
Suisse office at International Commerce Centre, Hong Kong. Management is scheduled to meet
with institutional investors throughout Tuesday, September 3.
- Morgan Stanley Global Healthcare Conference, to be held
September 9-11, 2013 at the Grand
Hyatt New York. Management is scheduled to meet with institutional
investors throughout the event.
For additional information, please contact the respective
institutional sales representative at each sponsoring bank.
About China Biologic Products, Inc.
China Biologic Products, Inc. (Nasdaq: CBPO), is a leading fully
integrated plasma-based biopharmaceutical company in China. The Company's products are used as
critical therapies during medical emergencies and for the
prevention and treatment of life-threatening diseases and
immune-deficiency related diseases. China Biologic is headquartered
in Beijing and manufactures over
20 plasma-based products through its indirect majority-owned
subsidiaries, Shandong Taibang Biological Products Co., Ltd. and
Guiyang Dalin Biologic Technologies Co., Ltd. The Company also has
an equity investment in Xi'an Huitian Blood Products Co., Ltd. The
Company sells its products to hospitals and other healthcare
facilities in China. For
additional information, please see the Company's website
www.chinabiologic.com.
Contact:
China Biologic Products, Inc.
Mr. Ming Yin
Vice President
Phone: +86-10-6598-3099
Email: ir@chinabiologic.com
ICR Inc.
Mr. Bill Zima
Phone: +86-10-6583-7511 or +1-646-405-5191
E-mail: bill.zima@icrinc.com
SOURCE China Biologic Products, Inc.